For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).